help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DENNESEN, P. J. W.
Right arrow Articles by BONTEN, M. J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DENNESEN, P. J. W.
Right arrow Articles by BONTEN, M. J. M.

Am. J. Respir. Crit. Care Med., Volume 163, Number 6, May 2001, 1371-1375

Resolution of Infectious Parameters after Antimicrobial Therapy in Patients with Ventilator-associated Pneumonia

PAUL J. W. DENNESEN, ANDRÉ J. A. M. van der VEN, ALPHONS G. H. KESSELS, GRAHAM RAMSAY, and MARC J. M. BONTEN

Departments of Medical Microbiology, Medical Technology Assessment and Surgery, University Hospital Maastricht, Maastricht, The Netherlands; and Department of Internal Medicine, Division of Infectious Diseases and AIDS, University Hospital Utrecht, Utrecht, The Netherlands

Although recommended durations of antimicrobial therapy for ventilator-associated pneumonia (VAP) range from 7 to 21 d, these are not based on prospective studies and little is known about the resolution of symptoms after start of antibiotics. Resolution of these symptoms was investigated in 27 patients. VAP was diagnosed on clinical, radiographic, and microbiological criteria, including quantitative cultures of bronchoalveolar lavage. All patients received appropriate antibiotic therapy. Highest temperatures, leukocyte counts, PaO2/FIO2 ratios, and semiquantitative cultures of endotracheal aspirates were recorded from start of therapy until Day 14. Resolution was defined as the first day that these parameters fulfilled the following definition: temperature =< 38° C, leukocytes =< 10 × 109/L, PaO2/FIO2 ratio >=  25 kPa, and no or +1 of bacterial growth of etiologic pathogens in cultures of endotracheal aspirate. VAP was caused by Enterobacteriaceae (n = 14), P. aeruginosa (n = 7), S. aureus (n = 6), H. influenzae (n = 3), and S. pneumoniae (n = 1). H. influenzae and S. pneumoniae were eradicated from tracheal aspirates, whereas Enterobacteriaceae, S. aureus, and P. aeruginosa persisted, despite in vitro susceptibility to antibiotics administered. Significant improvements were observed for all clinical parameters, most apparently within the first 6 d after start of antibiotics. Newly acquired colonization, especially with P. aeruginosa and Enterobacteriaceae, occurred in the second week of therapy. Six patients developed a recurrent episode of VAP, four of them with P. aeruginosa. Clinical responses to therapy for VAP occur within the first 6 d of therapy, endotracheal colonization with Gram-negative bacteria persists despite susceptibility to therapy, and acquired colonization usually occurs in the second week of therapy and frequently precedes a recurrent episode.




This article has been cited by other articles:


Home page
 ChestHome page
J. Dallas and M. Kollef
VAT vs VAP: Are We Heading Toward Clarity or Confusion?
Chest, February 1, 2009; 135(2): 252 - 255.
[Full Text] [PDF]

Home page
 ACCP Pulmonary Med Brd RevHome page
R. F. Grossman
Hospital-Acquired and Ventilator-Associated Pneumonia
ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 391 - 400.
[Full Text] [PDF]

Home page
 J Intensive Care MedHome page
M. B. Rosbolt, E. S. Sterling, and B. G. Fahy
The Utility of the Clinical Pulmonary Infection Score
J Intensive Care Med, January 1, 2009; 24(1): 26 - 34.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. R. Hauser
Pseudomonas aeruginosa: An Uninvited Guest Refuses to Leave
Am. J. Respir. Crit. Care Med., September 1, 2008; 178(5): 438 - 439.
[Full Text] [PDF]

Home page
 ERRHome page
J. Chastre and C. E. Luyt
Optimising the duration of antibiotic therapy for ventilator-associated pneumonia
Eur. Respir. Rev., August 1, 2007; 16(103): 40 - 44.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
S. M. Koenig and J. D. Truwit
Ventilator-Associated Pneumonia: Diagnosis, Treatment, and Prevention
Clin. Microbiol. Rev., October 1, 2006; 19(4): 637 - 657.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I. Porzecanski and D. L. Bowton
Diagnosis and treatment of ventilator-associated pneumonia.
Chest, August 1, 2006; 130(2): 597 - 604.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
K. A. Davis
Ventilator-Associated Pneumonia: A Review
J Intensive Care Med, July 1, 2006; 21(4): 211 - 226.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. H. Kollef
Microbiological Diagnosis of Ventilator-associated Pneumonia: Using the Data to Optimize Clinical Outcomes.
Am. J. Respir. Crit. Care Med., June 1, 2006; 173(11): 1182 - 1184.
[Full Text] [PDF]

Home page
 ChestHome page
A. F. Shorr and M. H. Kollef
Ventilator-Associated Pneumonia: Insights From Recent Clinical Trials
Chest, November 1, 2005; 128(5_suppl_2): 583S - 591S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. H. Kollef and K. E. Kollef
Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results
Chest, October 1, 2005; 128(4): 2706 - 2713.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. Povoa, L. Coelho, E. Almeida, A. Fernandes, R. Mealha, P. Moreira, and H. Sabino
C-reactive protein as a marker of ventilator-associated pneumonia resolution: a pilot study
Eur. Respir. J., May 1, 2005; 25(5): 804 - 812.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. L. Yershov, B. S. Jordan, C. H. Guymon, and M. A. Dubick
Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model
Eur. Respir. J., April 1, 2005; 25(4): 693 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia
Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 388 - 416.
[Full Text] [PDF]

Home page
 ChestHome page
F. Michel, B. Franceschini, P. Berger, J.-M. Arnal, M. Gainnier, J.-M. Sainty, and L. Papazian
Early Antibiotic Treatment for BAL-Confirmed Ventilator-Associated Pneumonia: A Role for Routine Endotracheal Aspirate Cultures
Chest, February 1, 2005; 127(2): 589 - 597.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C.-E. Luyt, V. Guerin, A. Combes, J.-L. Trouillet, S. B. Ayed, M. Bernard, C. Gibert, and J. Chastre
Procalcitonin Kinetics as a Prognostic Marker of Ventilator-associated Pneumonia
Am. J. Respir. Crit. Care Med., January 1, 2005; 171(1): 48 - 53.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. Afessa
From "Pro and Con" Debate to Evidence-Based Practice: Ventilator-Associated Pneumonia
Chest, May 1, 2004; 125(5): 1600 - 1602.
[Full Text] [PDF]

Home page
 ChestHome page
S. T. Micek, S. Ward, V. J. Fraser, and M. H. Kollef
A Randomized Controlled Trial of an Antibiotic Discontinuation Policy for Clinically Suspected Ventilator-Associated Pneumonia
Chest, May 1, 2004; 125(5): 1791 - 1799.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. Chastre, M. Wolff, J.-Y. Fagon, S. Chevret, F. Thomas, D. Wermert, E. Clementi, J. Gonzalez, D. Jusserand, P. Asfar, et al.
Comparison of 8 vs 15 Days of Antibiotic Therapy for Ventilator-Associated Pneumonia in Adults: A Randomized Trial
JAMA, November 19, 2003; 290(19): 2588 - 2598.
[Abstract] [Full Text] [PDF]

Home page
 J Intensive Care MedHome page
R. P. Baughman and M. A. Kerr
Ventilator-Associated Pneumonia Patients who Do Not Reduce Bacteria from the Lungs have a Worse Prognosis
J Intensive Care Med, September 1, 2003; 18(5): 269 - 274.
[Abstract] [PDF]

Home page
 ChestHome page
M. Beutz, G. Sherman, J. Mayfield, V. J. Fraser, and M. H. Kollef
Clinical Utility of Blood Cultures Drawn From Central Vein Catheters and Peripheral Venipuncture in Critically Ill Medical Patients
Chest, March 1, 2003; 123(3): 854 - 861.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Iregui, S. Ward, G. Sherman, V. J. Fraser, and M. H. Kollef
Clinical Importance of Delays in the Initiation of Appropriate Antibiotic Treatment for Ventilator-Associated Pneumonia*
Chest, July 1, 2002; 122(1): 262 - 268.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Critical Care Medicine in AJRCCM 2001
Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 565 - 583.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2001 American Thoracic Society 		  ATS 2008 State of the Art Course